Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
•Lack of success of most anti-amyloid trials in symptomatic AD is attributable in part to the pathology being too advanced.•Progress in quantifying tau and Aβ in plasma suggests that changes in these analytes may even predict AD presymptomatically.•Anti-Aβ immunotherapy should include secondary prev...
Gespeichert in:
| Veröffentlicht in: | Current opinion in neurobiology 2020-04, Vol.61, p.116-124 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!